Use of Predictive Markers in Oncology: Are Phase 3 Trials Always Required?

Publisher： Karger

E-ISSN： 1423-0232|81|1|1-2

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.1, 2011-09, pp. : 1-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Patients' Perceptions of Research Biopsies in Phase I Oncology Trials

By  

Oncology, Vol. 88, Iss. 2, 2014-10 ,pp. : 95-102

Karger

Access to resources Recommend Favorite

Suggestions from adolescents, young adults, and parents for improving informed consent in phase 1 pediatric oncology trials

By  

CANCER, Vol. 119, Iss. 23, 2013-12 ,pp. : 4154-4161

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predictive and prognostic markers in colorectal cancer

By Turkington Richard C   Coyle Vicky M   Johnston Patrick G   Eatock Martin M  

Personalized Medicine, Vol. 4, Iss. 3, 2007-08 ,pp. : 295-306

Future Medicine

Access to resources Recommend Favorite

The cetuximab experience: developing predictive biomarkers in oncology

By Harbison Christopher T   Horak Christine E   Khambata-Ford Shirin  

Personalized Medicine, Vol. 8, Iss. 2, 2011-03 ,pp. : 149-159

Future Medicine

Access to resources Recommend Favorite

Adverse event monitoring in oncology clinical trials

By Russell Jeffery S   Colevas A Dimitrios  

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1157-1165

Future Science

Access to resources Recommend Favorite